metformin has been researched along with Bipolar Disorder in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin may safely assist olanzapine-treated patients in body weight and carbohydrate metabolism control." | 9.12 | Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. ( Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M, 2007) |
| "Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome." | 8.87 | Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. ( Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK, 2011) |
| "Metformin was assessed as a treatment for weight gain in children taking olanzapine, risperidone, quetiapine, or valproate." | 5.31 | Metformin for weight loss in pediatric patients taking psychotropic drugs. ( Barton, BA; Cottingham, EM; Morrison, JA, 2002) |
| "Metformin may safely assist olanzapine-treated patients in body weight and carbohydrate metabolism control." | 5.12 | Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. ( Baptista, T; Beaulieu, S; Carrizo, E; Connell, L; Dávila, A; de Baptista, EA; El Fakih, Y; Fernández, V; Galeazzi, T; Gutiérrez, MA; Rangel, N; Serrano, A; Servigna, M; Uzcátegui, E; Uzcátegui, M, 2007) |
| "Olanzapine is an atypical antipsychotic that is useful in schizophrenia and bipolar affective disorder, but its use is associated with troublesome weight gain and metabolic syndrome." | 4.87 | Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. ( Goyal, N; Jana, AK; Praharaj, SK; Sinha, VK, 2011) |
| "The study investigated the risk of newly developed bipolar disorder (BD) in patients with polycystic ovary syndrome (PCOS) and examined the relationship between PCOS treatment (hormone therapy (clomiphene or cyproterone) or metformin) and risk of BD development." | 3.96 | Risk of bipolar disorder in patients with polycystic ovary syndrome: A nationwide population-based cohort study. ( Chen, SF; Hsu, CY; Shen, YC; Yang, YC, 2020) |
| "Metformin was assessed as a treatment for weight gain in children taking olanzapine, risperidone, quetiapine, or valproate." | 1.31 | Metformin for weight loss in pediatric patients taking psychotropic drugs. ( Barton, BA; Cottingham, EM; Morrison, JA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Nagy, LR | 1 |
| Rice, T | 1 |
| Coffey, BJ | 1 |
| Chen, SF | 1 |
| Yang, YC | 1 |
| Hsu, CY | 1 |
| Shen, YC | 1 |
| Kopel, J | 1 |
| Grooms, A | 1 |
| Ganapathy, V | 1 |
| Clothier, J | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Mennella, C | 1 |
| Dickstein, DP | 1 |
| Robinson, LA | 1 |
| Penzner, JB | 1 |
| Arkow, S | 1 |
| Kahn, DA | 1 |
| Berman, JA | 1 |
| Praharaj, SK | 1 |
| Jana, AK | 1 |
| Goyal, N | 1 |
| Sinha, VK | 1 |
| Baptista, T | 1 |
| Rangel, N | 1 |
| Fernández, V | 1 |
| Carrizo, E | 1 |
| El Fakih, Y | 1 |
| Uzcátegui, E | 1 |
| Galeazzi, T | 1 |
| Gutiérrez, MA | 1 |
| Servigna, M | 1 |
| Dávila, A | 1 |
| Uzcátegui, M | 1 |
| Serrano, A | 1 |
| Connell, L | 1 |
| Beaulieu, S | 1 |
| de Baptista, EA | 1 |
| Morrison, JA | 1 |
| Cottingham, EM | 1 |
| Barton, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metformin and Bipolar Disorder
| Article | Year |
|---|---|
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Humans; Hyp | 2011 |
1 trial available for metformin and Bipolar Disorder
| Article | Year |
|---|---|
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass Index; Body | 2007 |
6 other studies available for metformin and Bipolar Disorder
| Article | Year |
|---|---|
Combined Topiramate and Metformin Pharmacotherapy for Second-Generation Antipsychotic-Induced Weight Gain in Pediatric Bipolar Disorder and Aggression.
Topics: Aggression; Antipsychotic Agents; Bipolar Disorder; Child; Humans; Metformin; Topiramate; Weight Gai | 2022 |
Risk of bipolar disorder in patients with polycystic ovary syndrome: A nationwide population-based cohort study.
Topics: Bipolar Disorder; Clomiphene; Cohort Studies; Female; Humans; Metformin; Polycystic Ovary Syndrome | 2020 |
Metformin, valproic acid, and starvation induce seizures in a patient with partial SLC13A5 deficiency: a case of pharmaco-synergistic heterozygosity.
Topics: Adult; Amino Acid Substitution; Ammonia; Animals; Anticonvulsants; Autistic Disorder; Bipolar Disord | 2021 |
Metformin-Induced Type 1 Hypersensitivity in a Child with Antipsychotic-Induced Weight Gain.
Topics: Antipsychotic Agents; Bipolar Disorder; Child; Drug Hypersensitivity; Humans; Hypersensitivity, Imme | 2017 |
Electroconvulsive therapy for the treatment of refractory mania.
Topics: Antipsychotic Agents; Bipolar Disorder; Electroconvulsive Therapy; Female; Follow-Up Studies; Humans | 2011 |
Metformin for weight loss in pediatric patients taking psychotropic drugs.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Child; Dose-R | 2002 |